Vendor, Minneapolis, MN
Isola Therapeutics Inc.
UEI M3QDM72NME75, CAGE 890E6
3 awards and $7,485,417 obligated between June 20, 2024 and April 27, 2026, 67% under full and open competition, against 6.3 offers on average where reported. 1 of the awards trace back to a SAM.gov solicitation on this site.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $7,485,417 |
| National Institutes of Health | $0 |
Industries
NAICS on the awards, by dollars.
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 3 |
Solicitations it won
SAM.gov opportunities whose award USAspending attributes to this vendor.
- BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
Office of Assistant Secretary for Preparedness and Response, Barda - Aspr / Daappo / Barda DCMA
Award noticeNAICS 541714Minneapolis, MN75A50126C00005Awarded to Isola Therapeutics Inc. for $7,485,417
Posted Apr 27
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50126C00005Definitive Contract, April 27, 2026, Full and Open Competition, 1 offersSolicitation | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | The Purpose of This Award Is to Advance the Development of Isola'S Nebulization Therapy, a Medical Countermeasure Designed to Prevent and TrNAICS 541715, PSC AN13 | $7,485,417 |
| 75A50123C00031Definitive Contract, June 20, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | R&D for Endobronchial Lavage (Ebl) to Prevent and Treat Lung Damage from Pulmonary Chemical Agents Aoi #15: Redirect (Repurposing Drugs in RNAICS 541714, PSC AN14 | $0 |
| 75N91022C00018Definitive Contract, August 30, 2024, Full and Open Competition After Exclusion of Sources, 17 offers | NIH NCINational Institutes of Health | Phase I -Topic 431 - Drug Delivery by Endoesophageal Lavage (Eel) to Treat Esophageal CancerNAICS 541715, PSC AN12 | $0 |
- Places of performance
- Minnesota
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental DevelopmentAN12 Health R&D Services; Health Care Services; Applied ResearchAN14 Health R&D Services; Health Care Services; R&D Administrative Expenses
- Transactions
- 3 across 3 awards